Journals / Türk Oftalmoloji Dergisi / 2015 / Cilt: 45 - Sayı: 4

Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome

Sekonder Sjögren Sendromlu Hastalarda Sistemik İnfliksimab Tedavisinin Etkinliği

Pages
138–141
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J Ophthalmol 2015; 45: 138-141)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases.
📊
Key Findings & Data:Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjögren’s syndrome who began treatment with systemic infliximab.
💡
Conclusion & Impact:Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J Ophthalmol 2015; 45: 138-141)
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases. Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjögren’s syndrome who began treatment with systemic infliximab. Tear film break-up time (TBUT), anesthetized Schirmer’s 1 test, fluorescein staining test, and Ocular Surface Disease Index (OSDI) scores were recorded before treatment and in the 3rd and 6th months of treatment. Results: In the 3rd month of infliximab therapy, no significant changes were observed in Schirmer’s values, TBUT, fluorescein staining, or OSDI scores (p=0.260, p=0.357, p=0.190 and p=0.07, respectively). In the 6th month of infliximab therapy, no significant changes were observed in TBUT, fluorescein staining, Schirmer’s value or OSDI scores (p=0.510, p=0.320, p=0.220 and p=0.344, respectively). Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J Ophthalmol 2015; 45: 138-141)

Özet

Amaç: Çeşitli otoimmün hastalıklar ile birliktelik gösteren sekonder Sjögren sendromlu hastalarda sistemik infliksimab tedavisinin oküler yüzey ve gözyaşı fonksiyon testlerine etkisini araştırmak.Ge reç ve Yön tem: Prospektif olarak gerçekleştirilen bu çalışmaya sistemik infliksimab tedavisi başlanan 22 Sjögren sendromlu hastanın 22 gözü dahil edildi. Tedavi öncesinde, tedavinin 3. ve 6. ayında, gözyaşı filmi kırılma zamanı (GKZ), anestezili Schirmer 1 testi, floresein ile boyama testi, Oküler Yüzey Hastalık Indeksi (OYHİ) skorları kaydedildi. Bulgular: İnfliksimab tedavisinin 3. ayında Schirmer skorlarında, GKZ'sinde, floresein ile boyama testi ve OYHİ değerlerinde anlamlı bir değişiklik izlenmedi (sırasıyla p=0,260, p=0,357, p=0,190 ve p=0,07). İnfliksimab tedavisinin 6. ayında da GKZ, floresein ile boyama testi, Schirmer ve OYHİ skorlarında anlamlı bir değişiklik olmadığı izlendi (sırasıyla p=0,510, p=0,320, p=0,220 ve p=0,344).Sonuç: Romatoid artrit, Crohn hastalığı, ülseratif kolit, ankilozan spondilit gibi otoimmün hastalıklarda yaygın olarak kullanılan sistemik infliksimab tedavisinin oküler yüzey ve gözyaşı fonksiyon testleri üzerine olumlu bir etkisi izlenmedi

🔖

Cite This Article

TUNA, S., ALAN, S., TÜRKOĞLU, E. B., ÜNAL, M., TUNA, Y., ARMAN, M. İ. (2022). Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome. Türk Oftalmoloji Dergisi, Cilt: 45 - Sayı: 4, 138–141. https://ajindex.com/articles/637998

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. İskeleli G, Uslu H, Kayhan BA, Arslan OŞ, Sayılgan T, Melikoğlu M. Sjögren Sendromlu Hastalarda Kornea Duyarlılığı. Türk Oftalmol J. 2001;31:9-12
  2. Deveci H, Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s syndrome. Int Ophthalmol. 2014;34:1043-1048
  3. Hyon JY, Lee YJ, Yun PY. Management of ocular surface inflammation in Sjögren syndrome. Cornea. 2007;26:13-15
  4. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010;304:452-460
  5. Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Crow RW, Atkinson R, Ritter T, Bose S, Trousdale MD. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea. 2003;22:343-351
  6. Li Z, Choi W, Oh HJ, Yoon KC. Effectiveness of topical infliximab in a Mouse model of experimental dry eye. Cornea. 2012;31:25-31
  7. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren’s syndrome: potential therapeutic targets. Ann Rheum Dis. 2010;69:945-948
  8. Utine CA, Akpek EK. Sjögren Sendromu ve İlişkili Kuru Göz Sendromunun İmmunopatolojisi-Derleme. Türk Oftalmol J. 2010;40:97-106
  9. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431-437
  10. Cordero-Coma M, Anzaar F, Sobrin L, Foster CS. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm. 2007;15:99-104
  11. Brito-Zerón P, Sisó-Almirall A, Bové A, Kostov BA, Ramos-Casals M. Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother. 2013;14:279-289
  12. Toker E, Acar N, Kazokoğlu H. Sjögren Sendromuna Bağlı kuru Göz Hastalığında Topikal %0.1 Siklosporin A Tedavisinin Etkinliği. Türk Oftalmol J. 2003;33:324-330
  13. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B,Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjögren’s syndrome: results of therandomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270-1276
  14. Odorcic S, Keystone EC, Ma JJ. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Cornea. 2009;28:89-92